Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Understanding what stocks are favored by new investors can guide your choices. Explore current buying trends to make informed decisions.
27,622 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
The S&P 500 nudges higher as Brent crude hovers above $103, lifting energy names. Analysts flag the biggest things dr...
A diversified cybersecurity ETF now holds CrowdStrike alongside 30 other rivals, offering broad exposure as AI-driven...
Which core holding fits a long-term plan better: SPDR S&P 500 ETF Trust or Vanguard Total World Stock ETF? This guide...
As the fed's preferred inflation metric climbs above 4%, investors face questions about rate paths and portfolio reso...
FCX and NEM beat quarterly estimates, but 2026 headwinds and project timing are shaping whether one stock outperforms...
Two giants, one core goal: global exposure. This guide breaks down how Vanguard Total World iShares and URTH compare ...
Tensions with Iran are driving a puzzling market mix: gold retreats while equities slip only modestly, hinting at a b...
As markets wobble over a broader utility pullback, a regulated water utility stands out for steady payouts and depend...
What if a hidden obstacle stands between you and a successful investment journey? The great filter is a lens to spot ...
Investors and policymakers are debating the impact of politicians’ stock holdings as volatility grips markets. Expert...
Stocks rise on May 7, 2026 as AI-driven demand powers gains in the S&P 500 and SPY. Traders weigh earnings catalysts ...